Short description
Neurogenetic Pharmaceuticals is engaged in the R&D of therapeutics for neurodegenerative disorders such as Alzheimer’s disease.
Description
Neurogenetic Pharmaceuticals, Inc. (NGP) is a biopharmaceutical discovery and development company founded in 2009 which is focused on developing innovative drug therapies for use in the treatment of neurodegenerative disorders such as Alzheimer’s disease. Based in San Diego, Calif., the company’s next objective is to obtain an Investigational New Drug approval for its clinical candidate, NGP 555. This compound is expected to prevent the deposition of amyloid plaques in the brain, thereby precluding neuronal cell death and the dementia associated with AD. Future clinical trials will utilize specific Αβ biomarkers and/or brain scanning as an early diagnostic and to monitor drug efficacy in clinical trials. NGP licensed the GSM intellectual property from TPTX and expanded its portfolio to include issued patents in the US, Europe, China, India, Japan, Australia, and other countries.
Total funding
$$121212
Sign in for full access
Location
Del Mar, California, United States, North America
Founded on
January 1, 2009
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$1230 - 4560
Sign in for full access
Investors
Absolutely Noaccess
Sign in for full access
Founders
Rudolph Tanzi, Steven Wagner, William T. Comer